Prophylaxis for patients who have experienced a myocardial infarction: drug treatment, cardiac rehabilitation and dietary manipulation - guideline

National Institute for Clinical Excellence, North of England Evidence-based Guidelines Development Project
Record ID 32001000163
English
Authors' objectives:

To produce clinical practice guidelines on prophylaxis for patients who have experienced a myocardial infarction, in terms of drug treatment, cardiac rehabilitation and dietary manipulation.

Authors' recommendations: For patients with uncomplicated previous myocardial infarction, treatment should be offered to patients, initially with a beta-blocker and aspirin, and then with a statin and an ACE inhibitor. Referral for cardiac rehabilitation (with a substantial exercise component) should be offered, if not initiated, in hospital. For patients with previous myocardial infarction and heart failure, treatment should be offered to patients, initially with ACE inhibitor, and then a beta-blocker. Patients with moderate to severe heart failure should additionally be offered spironolactone. There is evidence to suggest value in a Mediterranean diet in patients with prior myocardial infarction and insulin therapy in the post-acute phase in patients with diabetes, although it has not been possible to assess the cost-effectiveness of these interventions.
Authors' methods: Review
Details
Project Status: Completed
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Rehabilitation
  • Myocardial Infarction
Contact
Organisation Name: National Institute for Clinical Excellence
Contact Address: MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.